Funding shake-up urged

Britain's system of funding university research is under fire as outdated. Nigel Williams reports.     

Ethics in Indigenous Research – Connecting with Community

The challenge for those responsible for funding, brokering and assessing the merit of proposed Indigenous research is to identify and then work co-operatively with appropriate representatives of Indigenous interests in order to increase the flow of benefits from research to Indigenous peoples. Experience in Australia has shown that this is not a straightforward process. In this paper we indicate some reasons why it is important for the research community to broker research with representative Indigenous organisations and to involve Indigenous peoples in the ethical assessment and conduct of research. We then identify some barriers to the achievement of these objectives and outline recently developed interventions from the field of health research that aim to promote a more effective working relationship between Indigenous peoples and members of the research community.

Conservation with a Gun: Understanding Landowner Attitudes to Deer Hunting in the Scottish Highlands

Conservation conflicts are often difficult to resolve due to a combination of poorly defined property rights, inadequate funding, high transaction costs, and contrasting value systems among stakeholders. This paper explores these barriers to collaboration in the context of the emerging deer crisis in the Scottish Highlands, where deer numbers are now higher than at any time in recorded history. In particular we explore the potential role of recreational hunting in the government’s strategy to contain rising deer numbers from the landowners’ perspective. Using both qualitative and quantitative analysis we find that hunting traditions and personal preferences, reinforced by antipathy to conservationists and their perceptions of land stewardship, are the major barriers to shooting more deer for conservation objectives. We conclude that an expansion of commercial hunting opportunities is the best practical approach to resolving the current conflict over deer, but conservationists and landowners must work together to create a more positive context for hunter-conservation initiatives and activities.

Lack of Correlation Between Antiobesity Policy and Obesity Growth Rates: Review and Analysis

ObjectiveTo review federal, state, and local antiobesity policies and to assess their relationships with obesity growth rates.MethodsWe performed a literature review, acquired data from governmental Internet sources, and assessed the statistical correlation between state antiobesity policies and the concavity in obesity growth rates.ResultsState-by-state antiobesity policies in 3 categories—taxation of sugared beverages and snacks, physical education and physical activity in schools, and funding for bicycle trails—were found to have no significant immediate correlation with the change in obesity growth rates.ConclusionsIneffective antiobesity legislation may be attributable to shortcomings in policy implementation. Behavioral economics and addressing large-scale cultural issues may have critical roles in promoting more healthful lifestyles. We propose that a systems-based paradigm evaluating complex interactions among pathophysiological, cultural, political, economic, and behavioral components can improve antiobesity policy implementation and should therefore be a research focus. (Endocr Pract. 2012;18:737-744)     

NIH disease funding levels and burden of disease

Background

An analysis of NIH funding in 1996 found that the strongest predictor of funding, disability-adjusted life-years (DALYs), explained only 39% of the variance in funding. In 1998, Congress requested that the Institute of Medicine (IOM) evaluate priority-setting criteria for NIH funding; the IOM recommended greater consideration of disease burden. We examined whether the association between current burden and funding has changed since that time.

Methods

We analyzed public data on 2006 NIH funding for 29 common conditions. Measures of US disease burden in 2004 were obtained from the World Health Organization''s Global Burden of Disease study and national databases. We assessed the relationship between disease burden and NIH funding dollars in univariate and multivariable log-linear models that evaluated all measures of disease burden. Sensitivity analyses examined associations with future US burden, current and future measures of world disease burden, and a newly standardized NIH accounting method.

Results

In univariate and multivariable analyses, disease-specific NIH funding levels increased with burden of disease measured in DALYs (p = 0.001), which accounted for 33% of funding level variation. No other factor predicted funding in multivariable models. Conditions receiving the most funding greater than expected based on disease burden were AIDS ($2474 M), diabetes mellitus ($390 M), and perinatal conditions ($297 M). Depression ($719 M), injuries ($691 M), and chronic obstructive pulmonary disease ($613 M) were the most underfunded. Results were similar using estimates of future US burden, current and future world disease burden, and alternate NIH accounting methods.

Conclusions

Current levels of NIH disease-specific research funding correlate modestly with US disease burden, and correlation has not improved in the last decade.     

Transcultural Diabetes Care in The United States – A Position Statement by the American Association of Clinical Endocrinologists

The American Association of Clinical Endocrinologists (AACE) has created a transculturalized diabetes chronic disease care model that is adapted for patients across a spectrum of ethnicities and cultures. AACE has conducted several transcultural activities on global issues in clinical endocrinology and completed a 3-city series of conferences in December 2017 that focused on diabetes care for ethnic minorities in the U.S. Proceedings from the “Diabetes Care Across America” series of transcultural summits are presented here. Information from community leaders, practicing health care professionals, and other stakeholders in diabetes care is analyzed according to biological and environmental factors. Four specific U.S. ethnicities are detailed: African Americans, Latino/Hispanics, Asian Americans, and Native Americans. A core set of recommendations to culturally adapt diabetes care is presented that emphasizes culturally appropriate terminology, transculturalization of white papers, culturally adapting clinic infrastructure, flexible office hours, behavioral medicine—especially motivational interviewing and building trust—culturally competent nutritional messaging and health literacy, community partnerships for care delivery, technology innovation, clinical trial recruitment and retention of ethnic minorities, and more funding for scientific studies on epigenetic mechanisms of cultural impact on disease expression. It is hoped that through education, research, and clinical practice enhancements, diabetes care can be optimized in terms of precision and clinical outcomes for the individual and U.S. population as a whole.Lay AbstractThe American Association of Clinical Endocrinologists (AACE) has created a diabetes care model for patients of different backgrounds. AACE led meetings in New York, Houston, and Miami with health care professionals and community leaders to improve diabetes care. Information from these meetings looked at biological and environmental diabetes risks. Four American patient groups were studied: African Americans, Latinos, Asian Americans, and Native Americans. Diabetes care should use culturally appropriate language and search for better ways to apply science and clinic design. Talking to patients more clearly can improve their diabetes control. There are many other needed changes in the American health care system discussed in this paper. It is hoped that through better education, research, and practice, diabetes care can be improved for the entire U.S. population. This means that important differences among patients' ethnic and cultural backgrounds are addressed.Executive Summary

• Cultural adaptation of evidence-based recommendations is a necessary component of optimal diabetes care.
• Biological factors that contribute to the pathophysiology of diabetes vary according to race and ethnicity and can be affected by social determinants that vary with culture.
• The “Transcultural Diabetes Nutrition Algorithm” was developed in 2010 to optimize diabetes nutrition care globally and represents a validated methodology where evidence-based recommendations from a source culture can be adapted and implemented in a different culture using a toolkit.
• The 2015 AACE Pan-American Workshop examined diabetes care in 9 Latin American nations and concluded that there should only be one level of diabetes care for a population and that level should be “excellent;” also, that A1C measurements should be utilized and that more educational and nutritional options are needed to optimize diabetes care.
• The “Diabetes Care Across America – A Series of Transcultural Summits” was an AACE program conducted in 2017 in New York, Houston, and Miami to examine cultural factors that influence diabetes care domestically; the findings of this program are presented here.
• The African American, Hispanic/Latino, Asian American, and Native American populations are each comprised of different ancestries, anthropometrics/body compositions and physical appearances, and cultures and degrees of acculturation, with a significant evidence base that associates specific gene variants with specific phenotypic traits affecting diabetes care.
• For each ethno-cultural population, health messaging and diabetes care will need to consider issues of potential distrust of health care professionals, history of discrimination, religious practices, food preferences, attitudes toward physical activity, and despite the full range of socio-economics, the impact of poverty on engagement, self-monitoring, adherence with lifestyle and medical recommendations, and recruitment for clinical trials.
• Diabetes care should be as precise as possible, incorporating clinical trial evidence that best reflects the ethno-cultural attributes of a specific patient, with particular emphasis on cardiovascular disease risk mitigation, technology to assess the effects of eating patterns on glycemic status, adjusting traditional eating patterns to more healthy options that are still acceptable to the patient, flexibility in lifestyle and medication recommendations that take into account cultural factors, and the utilization of community-based resources to improve implementation.
• Pragmatic first steps to prepare a diabetes practice for an ethno-culturally diverse patient population include: learning more about biological-cultural interactions; gaining experience with lifestyle and behavioral medicine, especially motivational interviewing; creating a safe and immersive clinical environment; incorporating translation services, social prescribing, wearable technologies, web-based resources, and community engagement; and establishing referral networks with clinical trialists in diabetes research to improve recruitment of different populations.

ABSTRACTAbbreviations: A1C = hemoglobin A1c; AACE = American Association of Clinical Endocrinologists; ABCD = adiposity-based chronic disease; BMI = body mass index; CPA = clinical practice algorithm; CPG = clinical practice guideline; DBCD = dysglycemia-based chronic disease; DPP = Diabetes Prevention Program; GWAS = genome-wide association study; HCP = health care professional(s); IHS = Indian Health Service; LDL = low-density lipoprotein; MetS = metabolic syndrome; T2D = type 2 diabetes mellitus; tDNA = transcultural Diabetes Nutrition Algorithm; TG = triglyceride; WC = waist circumference     

Funding source and research report quality in nutrition practice-related research

Background

The source of funding is one of many possible causes of bias in scientific research. One method of detecting potential for bias is to evaluate the quality of research reports. Research exploring the relationship between funding source and nutrition-related research report quality is limited and in other disciplines the findings are mixed.

Objective

The purpose of this study is to determine whether types of funding sources of nutrition research are associated with differences in research report quality.

Design

A retrospective study of research reporting quality, research design and funding source was conducted on 2539 peer reviewed research articles from the American Dietetic Association''s Evidence Analysis Library® database.

Results

Quality rating frequency distributions indicate 43.3% of research reports were rated as positive, 50.1% neutral, and 6.6% as negative. Multinomial logistic regression results showed that while both funding source and type of research design are significant predictors of quality ratings (χ2 = 118.99, p<0.001), the model''s usefulness in predicting overall research report quality is little better than chance. Compared to research reports with government funding, those not acknowledging any funding sources, followed by studies with University/hospital funding were more likely to receive neutral vs positive quality ratings, OR = 1.85, P <0.001 and OR = 1.54, P<0.001, respectively and those that did not report funding were more likely to receive negative quality ratings (OR = 4.97, P<0.001). After controlling for research design, industry funded research reports were no more likely to receive a neutral or negative quality rating than those funded by government sources.

Conclusion

Research report quality cannot be accurately predicted from the funding source after controlling for research design. Continued vigilance to evaluate the quality of all research regardless of the funding source and to further understand other factors that affect quality ratings are warranted.     

Phytochemical investigation on the roots of Juglans mandshurica and their chemotaxonomic significance

Phytochemical research of the roots of Juglans mandshurica Maxim. (Juglandaceae) verified 37 secondary metabolites, including thirteen diarylheptanoids (1–13), five naphthoquinones (14–18), five tetralones (19–23), three lignans (24–26), three phenols (27–29), two anthraquinones (30–31), two triterpenoids (32–33), two secoiridoids (34–35), one naphthalenyl glycoside (36), and one flavonoid (37). The chemical structures of these constituents were elucidated by NMR spectroscopy and compared with data from the literature. This is the first confirmation of the presence of ten compounds (6, 12, 16, 18, 24–26, 30, 32–33) isolated from the family Juglandaceae, two compounds (1 and 8) from the genus Juglans, and four compounds (27, 31, 34–35) from J. mandshurica. The isolation and chemotaxonomic significance of the metabolites from the roots of J. mandshurica were described in this study.     

Phytochemical and chemotaxonomic study on Ficus tsiangii Merr. ex Corner

Thirty-four compounds, including ten coumarins (1–10), thirteen flavonoids (11–23), three triterpenoid, one lignanoid (24), seven triterpenes (25–31) and three other compounds (32–34), were isolated from the stems of Ficus tsiangii Merr. ex Corner (F. tsiangii). Their structures were identified as xanthyletin (1), coumarin (2), umbelliferone (3), isoangenomalin (4), dihydroxanthyletin (5), scopoletin (6), nodakenetin (7), 6,7-dihydroxy-coumarin (8), 4'-O-β- glucopyranosyl-3'-hydroxy-nodakenetin (9), 6-carboxy-umbelliferone (10), 5,7,4'-trimethoxy- 3'-hydroxy-aurone (11), apigenin (12), naringenin (13), genistein (14), luteolin (15), prunetin (16), chrysoeriol (17), 5,6,7,-trihydroxy-4'-methoxy-flavone (18), eriodictyol (19), isocarthamidin (20), 5,7,2',4'-tetrahydroxyflavone (21), taxifolin (22), dihydro-kaempferol (23), syringeresinol (24), taraxerol (25), taraxerone (26), lupeolacetate (27), 3-acetoxy-12- oleanene-11-ketone (28), 3-acetoxy-lup-12,20(29)-diene (29), oleanic acid (30), ursolic acid (31), 3,4,5-trimethoxy phenyl-1-O-glucopyranoside (32), 8'-hydroxyabscisic acid glucoside (33) and adenosine (34). Among them, all compounds except 3, 14, 17, 25, 26, 30, 33 were isolated from the plant for the first time, and compounds 1, 4, 5, 8–11, 16, 18, 20, 23, 24, 32, 34 were firstly reported from the genus Ficus. The chemotaxonomic significance of these compounds was summarized as follows.     

Secondary metabolites from Corispermum mongolicum Iljin and their chemotaxonomic significance

A phytochemical investigation of the whole plant of Corispermum mongolicum Iljin (Chenopodiaceae) led to the isolation of thirty-eight compounds, including thirteen phenylpropanoids (1–13), six megastigmane-type norsesquiterpenoids (14–19), eight sterols (20–27), two flavonoid glycosides (28, 29), one alkaloid (30), two aromatic glycosides (31, 32), one aliphatic glycoside (33), one triterpenoid (34), one diterpenoid (35), two cerebrosides (36, 37) and one monogalactosyldiacyl glycerol (38). The chemical structures of these compounds were elucidated on the basis of spectral data and by comparisons of spectroscopic data with reported values in the literature. Twenty-eight compounds (1, 2, 4–16, 19, 20, 23–27, 30, 32–35, 37) were first found in the family Chenopodiaceae. The chemotaxonomic significance of these compounds is discussed.     

New steroid and other compounds from non-polar extracts of Clusia burle-marxii and their chemotaxonomic significance

Phytochemical investigation of the non-polar extract of Clusia burle-marxii led to the identification of a new steroid (1), along with friedelinol (2), β-sitosterol (3), friedelin (4), stigmast-5-en-3β,7β-diol (5), stigmast-5-en-3β,7α-diol (6), stigmasterol (7), sitostenone (8), betulinic acid (9), butyrospermol (10), euphol (11), betulin aldehyde (12), 2,2-dimethyl-5-hydroxy-7-phenyl-chromane (13), 6-deoxyisojacareubin (14), padiaxanthone (15) and betulonic acid (16). This is the first report of the identification of compounds 5, 6 and 10 in the family, the first report of compounds 14 and 15 in the genus, and the first report of compounds 2, 3, 7, 8, 12, 16 in the species. Chemotaxonomic significance of these compounds is described herein.     

Chemical constituents of the Piper crocatum leaves and their chemotaxonomic significance

Chemical study of Piper crocatum leaves has led to isolation of a new megastigmane glucoside isomer (18), along with 23 known compounds including fifteen phenolic compounds (1–15), two monoterpenes (16 and 17), three sesquiterpenes (19–21), a phenolic amide glycoside (22), a neolignan (23), and a flavonoid C-glycoside (24). Structures of these compounds were identified via spectroscopic methods and compared with those reported in the literature. Seven compounds (7, 11, 13, 14, 17, 20, and 24) from the P. crocatum species and 17 others (1–6, 8–10, 12, 15–16, 18–19, and 21–23) from the Piper genus and Piperaceae family were isolated and reported for the first time. Furthermore, this study discusses chemotaxonomic relations between P. crocatum and other Piper species.     

Big Science vs. Little Science: How Scientific Impact Scales with Funding

Agencies that fund scientific research must choose: is it more effective to give large grants to a few elite researchers, or small grants to many researchers? Large grants would be more effective only if scientific impact increases as an accelerating function of grant size. Here, we examine the scientific impact of individual university-based researchers in three disciplines funded by the Natural Sciences and Engineering Research Council of Canada (NSERC). We considered four indices of scientific impact: numbers of articles published, numbers of citations to those articles, the most cited article, and the number of highly cited articles, each measured over a four-year period. We related these to the amount of NSERC funding received. Impact is positively, but only weakly, related to funding. Researchers who received additional funds from a second federal granting council, the Canadian Institutes for Health Research, were not more productive than those who received only NSERC funding. Impact was generally a decelerating function of funding. Impact per dollar was therefore lower for large grant-holders. This is inconsistent with the hypothesis that larger grants lead to larger discoveries. Further, the impact of researchers who received increases in funding did not predictably increase. We conclude that scientific impact (as reflected by publications) is only weakly limited by funding. We suggest that funding strategies that target diversity, rather than “excellence”, are likely to prove to be more productive.     

Health research funding: Members' of Parliament knowledge of and attitudes toward health research and funding

Background

Establishment of the Canadian Institutes of Health Research (CIHR) in 2000 resulted in increased funding for health research in Canada. Since 2001, the number of proposals submitted to CIHR that, following peer review, are judged to be of scientific merit to warrant funding, has grown by 77%. But many of these proposals do not receive funding because of budget constraints. Given the role of Members of Parliament in setting government funding priorities, we surveyed Members of Parliament about their knowledge of and attitudes toward health research, health research funding and CIHR.

Methods

All Members of Parliament were invited to participate, or to designate a senior aide to participate, in a 15-minute survey of knowledge of and attitudes toward health research, health research funding and CIHR. Interviews were conducted between July 15, 2006, and Dec. 20, 2006. Responses were analyzed by party affiliation, region and years of service as a Member of Parliament.

Results

A total of 101 of 308 Members of Parliament or their designated senior aides participated in the survey. Almost one-third of respondents were senior aides. Most of the respondents (84%) were aware of CIHR, but 32% knew nothing about its role. Participants believed that health research is a critical component of a strong health care system and that it is underfunded. Overall, 78% felt that the percentage of total government spending directed to health research funding was too low; 85% felt the same way about the percentage of government health care spending directed to health research. Fifty-four percent believed that the federal government should provide both funding and guidelines for health research, and 66% believed that the business sector should be the primary source of health research funding. Participants (57%) most frequently defined health research as study into cures or treatments of disease, and 22% of participants were aware that CIHR is the main federal government funding organization for health research. Participants perceived health research to be a low priority for Canadian voters (mean ranking 3.8/10, with 1 being unimportant and 10 being extremely important [SD 1.85]).

Interpretation

Our results highlight significant knowledge gaps among Members of Parliament regarding health research. Many of these knowledge gaps will need to be addressed if health research is to become a priority.Over the past 8 years, health research has been an important but declining priority for the federal government. The development of the Canada Foundation for Innovation, the Canada Research Chairs, Genome Canada, the Networks of Centres of Excellence, the Canadian Health Services Foundation and the Canadian Institutes of Health Research (CIHR)¹ reflects this initial interest. Although most of these programs receive multi-year funding, CIHR receives annual funding from the federal government. However, its annual increases have not risen proportionately with the number of requests for funding it receives each year.CIHR is the federal funding body for health research and consists of 13 institutes. It supports 4 pillars of research: biomedical research, clinical research, social and cultural aspects of health and population health research, and health services and systems research. With the formation of CIHR,² federal funding for health research increased from $289 million in 2000 to $553 million in 2002, with subsequent 5%–6% annual increases until 2006. That year, the increase was 2.4%.³ The initial increases in funding stimulated a sharp rise in the number of grants submitted and funded annually. In the 2006 competition, the increase in funding was lower than expected and the success rate in the open competition fell to 16% from the mean rate of 31.7% in previous years. As a result, 60% of peer-reviewed grants rated as very good or excellent were not funded, as compared with 38% in 2001 (CIHR: unpublished data,2007).Because Members of Parliament vote annually to determine CIHR''s budget for funding health research, we surveyed Members of Parliament and their senior aides about their knowledge of and attitudes toward health research, health research funding and CIHR.     

Chemical constituents from Piper boehmeriifolium (Miq.) Wall. ex C. DC

The chemical investigation of whole plants Piper boehmeriifolium (Miq.) Wall. ex C. DC. led to the isolation of 22 compounds, including two lignans (1–2), sixteen amide alkaloids (3–18), one diterpene (19), two monoterpenes (20–21), and one phenylpropanoid (22). Their structures were elucidated by extensive spectroscopic analyses including NMR, MS, and by comparison with the literature. Compounds 1–2, 6–7, 11–12, 14, and 17–22 were firstly isolated from P. boehmeriifolium, while compounds 2, and 19–20 were isolated from Piper genus for the first time. The chemotaxonomic significance of these isolated compounds is discussed.     

Chemical constituents from Polygonum capitatum Buch-Ham. ex D. Don

This work describes the isolation and characterization of thirty-one compounds from Polygonum capitatum Buch-Ham. ex D. Don, including two triterpenes (1–2), ten flavonoids (7–16), nine lignans (17–25), nine phenolic compounds (4–7, 26–31) and one anthraquinones (3). Their structures were elucidated on the basis of various spectroscopic methods (UV, IV and NMR, including 2D experiments). It was the first report of compounds 13, 15, 17, 24, 25, 28, 29, 30, 31 from the genus Ploygonum, and the first report of compounds 13, 15, 17, 24, 25 from the family Polygonaceae.     

Chemical constituents of Leucas zeylanica and their chemotaxonomic significance

Chemical study of the whole plant of Leucas zeylanica (L.) B. Br. has led to isolation of a new norditerpenoid isomer (1), along with 29 known compounds, including one norditerpenoid (2), three flavonoid glycosides (3–5), six flavonoids (6–11), two phytosterols (12–13), two phenylpropanoids (14, 19), two phthalate esters (15, 16), two phenolic compounds (17, 18), five terpenoids (20–24), one aliphatic glycoside (25), one nucleobase (26), one amino acid (27), two alkaloids (28–29), and one cytochalasin (30). The structures of these compounds were identified using NMR spectroscopic methods and comparing them with those previously reported. Twelve compounds (6, 15, 17–20, 22, 23, 26–29) were isolated for the first time from Leucas zeylanica and ten others (2, 4, 5, 7, 14, 16, 21, 24, 25, 30) from the Leucas genus. This study also discusses the chemotaxonomic relationships between Leucas zeylanica and other species of Leucas.     

Chemical constituents from Lagopsis supina (Steph.) Ik.-Gal. ex Knorr

Phytochemical investigation of the whole plants of Lagopsis supina (Steph.) Ik.-Gal. ex Knorr. led to the isolation of 18 compounds (1–18), including ten phenylethanoid glycosides (1–10), one phenylmethanoid glycoside (11), four megastigmane glycosides (12–15), and three monoterpenoid glycosides (16–18). Lagopsides A (1) and B (2) were identified as new phenylethanoid glycosides. This is the first report of compounds 7, 11, 12, 15, and 16 from the Labiatae family, while compounds 4–6, 8–10, 13–14, and 17–18 were isolated from the genus Lagopsis for the first time. The chemotaxonomic significance of these isolated compounds was summarized.     

Phytochemical study of Joannesia princeps Vell. (Euphorbiaceae) leaves

A phytochemical study of chloroform-methanol and methanol extracts of Joannesia princeps Vell. Leaves led to the isolation of twenty eight compounds, including two α-ionones (2, 5), three glycosylated monoterpenes (1, 3, 4), eight phenolic compounds (6, 8, 9, 12, 14, 17, 18, 24), two gallotannins (10, 11), twelve flavonoids (7, 15, 16, 19, 20–23, 25–28), and one lignan (13). The structural characterization of the isolated compounds was performed by spectroscopic data and comparison with the literature. All compounds were isolated from this species and from the genus Joannesia for the first time. The chemotaxonomic importance of these metabolites is therefore summarized.     

Phytochemical and chemotaxonomic study on the leaves of Rhododendron dauricum L

The phytochemical study of the leaves of Rhododendron dauricum L. (Ericaceae) led to the isolation and identification of 44 compounds, including fourteen triterpenoids (1–14), thirteen flavonoids (15–27), eight phenols (28–35), four grifolin derivatives (36–39), two diterpenoids (40–41), two megastigmanes (42–43) and one sesquiterpenoid (44). The chemical structures of these compounds were identified by spectroscopic data and compared with those previously reported. This is the first report on compounds 25, 31, 34, 40, 43, and 44 from the family Ericaceae, compound 42 from the genus Rhododendron, and compounds 24, 28, 30, 32, 33 and 35 from R. dauricum. The chemotaxonomic significance of these compounds was discussed.